Medscape is available in 5 Language Editions – Choose your Edition here.


Ophthalmologic Manifestations of Behcet Disease

  • Author: Mounir Bashour, MD, PhD, CM, FRCSC, FACS; Chief Editor: Hampton Roy, Sr, MD  more...
Updated: Mar 21, 2016


Behçet disease is a systemic disorder characterized by recurrent aphthous ulcers and intraocular inflammation. The clinical triad of uveitis with recurrent oral and genital ulcers bears the name of Hulusi Behçet, a Turkish dermatologist who described 3 patients who had this triad.

The Behçet's Disease Research Committee of the Ministry of Health and Welfare of Japan first proposed formal diagnostic criteria in 1972. This set of criteria, which has been used throughout the world, classifies disease findings into 4 major criteria and 5 minor criteria. When all 4 major criteria are met, the disease is said to be of the complete type, whereas the incomplete type consists of various combinations of major and minor criteria, with added weight given to ocular disease.

In 1990, The International Study Group (ISG) for Behçet's Disease proposed a separate set of diagnostic criteria for Behçet disease. Based on these criteria, a diagnosis of Behçet disease requires recurrent oral ulceration and at least 2 additional criteria, including recurrent genital ulcers, ocular lesions, skin lesions, and a positive pathergy test. The ISG criteria for Behçet disease have excellent specificity, but lack sensitivity. The International Criteria for Behçet’s Disease (ICBD) was created in 2006, as a replacement to the ISG criteria. For ICBD, vascular lesions were added, while oral aphthosis is no longer mandatory. Accruing 3 or more points is an indication of the diagnosis of Behçet disease (genital aphthosis, 2 points; eye lesions, 2 points; and the remaining each are 1 point).

A recent study compared the performance of the ISG and ICBD criteria. Their sensitivity, specificity, and accuracy (percent agreement), were tested in 3 independent cohorts of patients from the Far East (China), Middle East (Iran), and Europe (Germany). The sensitivity for ISG criteria was, respectively, 65.4%, 78.1%, and 83.7%, and, for ICBD, was 87%, 98.2%, and 96.5%. The specificity for ISG was, respectively, 99.2%, 98.8%, and 89.5%, and, for ICBD was 94.1%, 95.6%, and 73.7%. The accuracy for ISG was 74.2%, 85.5%, and 85.5%, and, for ICBD was 88.9%, 97.3%, and 89.5%. The conclusion is that ICBD has better sensitivity and accuracy than ISG.[1]

Other Medscape Reference articles on Behçet disease include Behcet disease (Dermatology) and Behcet disease (Rheumatology).



The cause and the pathogenesis of Behçet disease remain unknown. More than one mechanism seems to be operative in the pathogenesis of Behçet syndrome, including genetic and environmental factors, causing different manifestations of the syndrome. Several clues suggest the role of environmental factors and, especially, microorganisms, in the pathogenesis. These include clinical findings such as a decrease in the frequency of a positive pathergy reaction with surgical cleaning of the skin before the procedure, the acne-arthritis association carrying similar features to acne-associated reactive arthritis, a higher rate of tonsillectomy, cold sores, late birth order, higher number of siblings, history of travel to countries with a high incidence of Behçet syndrome, and earlier age at first sexual intercourse. Moreover, basic research on both viruses and bacteria suggests that microorganisms may be playing a role, possibly through heat-shock proteins and T-cell hypersensitivity.[2]

The tumor necrosis factor-alpha (TNF-alpha) pathway is likely involved in the pathophysiology of Behçet disease. The frequency of the R92Q TNFRSF1A mutation in patients with Behçet disease is significantly higher than that in control subjects (P = .006 by the Fisher exact test) and is associated with an increased risk of extracranial venous thrombosis.




United States

The prevalence of Behçet disease is estimated to be only 1 case per 300,000 persons per year.

In a university hospital setting, Behçet disease was responsible for 12-20% of cases of uveitis in Japan, compared with only 0.2-0.4% in the United States.


Behçet disease occurs worldwide, with a predominance among Asians, North Africans, and Europeans who live between the latitudes of 30-45°N.

Behçet disease is one of the main causes of endogenous uveitis in Japan and Turkey, with prevalence rates of 1 case per 10,000 population and 8-30 cases per 10,000 population, respectively.


The prevalence of Behçet disease exhibits a strong geographic variation and has a unique geographic distribution, being most prevalent along the ancient Silk Road linking Rome with China, which was used for centuries as a trade passage.[3]

The prevalence of Behçet disease is highest in Turkey, in the countries bordering the Mediterranean, in the Mideast, in the Far East, and in Japan, where it is 1 case per 1000 population.

Behçet disease occurs less frequently in northern Europe, the United States, and the United Kingdom.

The prevalence of Behçet disease in African Americans is 1 case per 100,000 population.


The male-to-female ratio varies with ethnic origin; androtropism is still observed in Arabian countries, with a ratio of 2.3:1, whereas female predominance is seen in some European countries and in the United States.[3]


The mean age at onset is in the third decade of life. However, when Behçet disease occurs in males aged 15-25 years, it takes a more serious form.

Contributor Information and Disclosures

Mounir Bashour, MD, PhD, CM, FRCSC, FACS Assistant Professor of Ophthalmology, McGill University Faculty of Medicine; Clinical Assistant Professor of Ophthalmology, Sherbrooke University; Medical Director, Cornea Laser and Lasik MD

Mounir Bashour, MD, PhD, CM, FRCSC, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American College of International Physicians, American College of Surgeons, American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Mechanical Engineers, American Society of Ophthalmic Plastic and Reconstructive Surgery, Biomedical Engineering Society, Canadian Medical Association, Canadian Ophthalmological Society, Contact Lens Association of Ophthalmologists, International College of Surgeons US Section, Ontario Medical Association, Quebec Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

R Christopher Walton, MD Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, University of Tennessee College of Medicine

R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Retina Society, American College of Healthcare Executives, American Uveitis Society

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

John D Sheppard, Jr, MD, MMSc Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard, Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, American Uveitis Society

Disclosure: Nothing to disclose.

  1. Davatchi F. Diagnosis/Classification Criteria for Behcet's Disease. Patholog Res Int. 2012. 2012:607921. [Medline]. [Full Text].

  2. Hatemi G, Yazici H. Behçet's syndrome and micro-organisms. Best Pract Res Clin Rheumatol. 2011 Jun. 25(3):389-406. [Medline].

  3. Houman MH, Hamzaoui K. Promising new therapies for Behcet's disease. Eur J Intern Med. 2006 May. 17(3):163-9. [Medline].

  4. Torres RM, Yanez B, Herreras JM, Calonge M. [Ocular Behcet disease. Retrospective study]. Arch Soc Esp Oftalmol. 2004 Dec. 79(12):599-603. [Medline].

  5. Pipitone N, Boiardi L, Olivieri I, et al. Clinical manifestations of Behcet's disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol. 2004. 22(6 Suppl 36):S46-51. [Medline].

  6. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004 Sep. 138(3):373-80. [Medline].

  7. Kaya TI. Genetics of Behçet's Disease. Patholog Res Int. 2012. 2012:912589. [Medline]. [Full Text].

  8. Dursun A, Durakbasi-Dursun HG, Dursun R, Baris S, Akduman L. Angiotensin-converting enzyme gene and endothelial nitric oxide synthase gene polymorphisms in Behçet's disease with or without ocular involvement. Inflamm Res. 2009 Mar 3. [Medline].

  9. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012 Jan 11. [Medline].

  10. Okada AA, Stanford M, Tabbara K. Ancillary testing, diagnostic/classification criteria and severity grading in Behçet disease. Ocul Immunol Inflamm. 2012 Dec. 20(6):387-93. [Medline].

  11. Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behçet disease. A review. Neurologist. 2005 Mar. 11(2):80-9. [Medline].

  12. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001 Nov. 44(11):2686-92. [Medline].

  13. Evereklioglu C. Ocular Behçet disease: current therapeutic approaches. Curr Opin Ophthalmol. 2011 Nov. 22(6):508-16. [Medline].

  14. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, et al. Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012. 6:5-12. [Medline]. [Full Text].

  15. Baldassano VF Jr. Ocular manifestations of rheumatic diseases. Curr Opin Ophthalmol. 1998 Dec. 9(6):85-8. [Medline].

  16. Borruat FX. Neuro-ophthalmologic manifestations of rheumatologic and associated disorders. Curr Opin Ophthalmol. 1996 Dec. 7(6):10-8. [Medline].

  17. Bredvik BK, Trocme SD. Ocular manifestations of immunological and rheumatological inflammatory disorders. Curr Opin Ophthalmol. 1996 Dec. 7(6):91-5. [Medline].

  18. Dinowitz K, Aldave AJ, Lisse JR, Trocme SD. Ocular manifestations of immunologic and rheumatologic inflammatory disorders. Curr Opin Ophthalmol. 1994 Dec. 5(6):91-8. [Medline].

  19. Eldem B, Onur C, Ozen S. Clinical features of pediatric Behcet's disease. J Pediatr Ophthalmol Strabismus. 1998 May-Jun. 35(3):159-61. [Medline].

  20. George RK, Chan CC, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Behcet's disease. Surv Ophthalmol. 1997 Sep-Oct. 42(2):157-62. [Medline].

  21. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999 Oct 21. 341(17):1284-91. [Medline].

  22. Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behcet's syndrome. Drugs. 1991 Nov. 42(5):796-804. [Medline].

Treatment modalities currently used in Behçet disease according to clinical symptoms.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.